Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Deleterious PALB2 Gene Mutation”

8 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 8 of 8 results

Not applicableLooking for participantsNCT04960839
What this trial is testing

Prophylactic Irradiation to the Contralateral Breast for BCAs Patients

Who this might be right for
Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University 323
Testing effectiveness (Phase 2)WithdrawnNCT06392841
What this trial is testing

Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Deleterious HRR Gene MutationBRCA1 Gene Mutation+7 more
Qian Qin
Testing effectiveness (Phase 2)Active Not RecruitingNCT04584255
What this trial is testing

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

Who this might be right for
Stage I Breast CancerStage II Breast CancerStage III Breast Cancer+5 more
Dana-Farber Cancer Institute 62
Not applicableStudy completedNCT03075735
What this trial is testing

Prospective Multicentre Cohort Study PROREPAIR-B (mCRPC)

Who this might be right for
Prostate Cancer
Centro Nacional de Investigaciones Oncologicas CARLOS III 408
Testing effectiveness (Phase 2)Ended earlyNCT04171700
What this trial is testing

Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes

Who this might be right for
Solid Tumor
pharmaand GmbH 83
Testing effectiveness (Phase 2)Ended earlyNCT03140670
What this trial is testing

Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy

Who this might be right for
Pancreatic Cancer
Abramson Cancer Center at Penn Medicine 46
Not applicableActive Not RecruitingNCT02760849
What this trial is testing

Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations

Who this might be right for
Deleterious BARD1 Gene MutationDeleterious BRCA1 Gene MutationDeleterious BRCA2 Gene Mutation+11 more
M.D. Anderson Cancer Center 374
Testing effectiveness (Phase 2)Active Not RecruitingNCT05033756
What this trial is testing

Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO

Who this might be right for
Malignant Neoplasm of BreastBreast Cancer
Institut fuer Frauengesundheit 11